PapersPMID:21208586
L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- RCT · 8 weeks
- Dose studied, every finding
- L-theanine 400 mg/d added to ongoing antipsychotic
- Population, every finding
- Chronic schizophrenia or schizoaffective disorder (DSM-IV); antipsychotic treatment continued in both arms as background; 8-week 2-center trial; PANSS 3-dimensional model
What moved
How to read these marks →“Compared with placebo, L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores (measured by the PANSS 3-dimensional model).”
- Decreases PANSS positive subscale score
very limited
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- patients with chronic DSM-IV schizophrenia or schizoaffective disorder on antipsychotic treatment
- Participants
- 60
- Comparator
- placebo
- Duration
- 56 days
- Endpoints measured
- 8